<DOC>
	<DOCNO>NCT01002495</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability catheter base injection VM202 heart .</brief_summary>
	<brief_title>Gene Therapy Treatment Chronic Stable Angina</brief_title>
	<detailed_description>A phase I/II , open label , dose-escalation , multicenter , 12 month study design assess safety tolerability catheter base percutaneous myocardial injection VM202 patient chronic refractory myocardial ischemia . The study consist three ( 3 ) cohort total 4 subject enrol cohort . Endocardial injection perform MyoStar Injection Catheter guidance NOGA XP Cardiac Navigation System .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Age ≥ 21 year , less equal 75 year . Stable chronic refractory angina classify Canadian Cardiovascular Society ( CCS ) functional class II IV Left ventricular ejection fraction ( LVEF ) ≥30 % ≤ 50 % ; Clinical sign symptom significant ischemia treadmill test Stress imaging ( SPECT , Echo CARDIAC MRI acceptable ) Subjects must able complete minimum 3 minute , 10 minute Modified Bruce treadmill protocol . Patients maximal medical therapy include least 2 follow ( unless hemodynamic parameter intolerance contraindicate use ) : ( ) Long act nitrate , ( b ) Beta Blocker ( c ) Calcium Channel Blocker ( ) Ranolazine . Optimal medical regimen subject decide refer cardiologist principal investigator . Patients must stable medical regimen 30 day prior enrollment . Coronary angiogram within 1 year confirm presence coronary disease amenable standard revascularization procedure . Candidates must eligible revascularization procedure . The participant his/her coronary film must discuss independent cardiac surgeon must deny CABG PTCA . Participants marginal poor candidate conventional revascularization consider eligible risk perform CABG PTCA procedure outweigh potential benefit and/or procedure unlikely offer worthwhile clinical benefit . The criterion define case may include , may limit , follow example : Diffuse distal vessel disease Chronic occlusion Unprotected leave main stenosis Tortuous severely angulate vessel Severely calcify vessel Small vessel ( &lt; 2.5mm ) Subjects childbearing potential must take acceptable measure prevent pregnancy course study . Subject capable understanding protocol signing informed consent document prior study related procedure . Subjects undergone successful revascularization procedure within 6 month enrollment ; MI , unstable angina require &gt; 24 hour hospitalization , percutaneous coronary intervention , within last 90 day ; Stroke TIA within last 180 day ; Predominant CHF symptom ; Hemodynamically significant severe primary valvular heart disease , unless correct properly functional prosthetic valve ; Uncontrolled hypertension define systolic BP 170 mmHg diastolic &gt; 90 mmHg baseline/ screen evaluation ; Sustained ventricular tachycardia automatic implantable cardiodefibrillator ( AICD ) fire within last 180 day ; History ventricular fibrillation ; Use MyoStar catheter may appropriate patient prosthetic valve . Patients mechanical valve risk injury due interventional approach exclude ; Subjects comorbidity may interfere ability perform maximal treadmill test ( e.g . severe arthritis , musculoskeletal disorder , COPD ) ; Subjects history malignancy , know active malignancy , new screen find malignant neoplasm ; Patients family history colon cancer first degree relative unless undergone colonoscopy last 12 month negative finding ; Elevated PSA unless prostate cancer exclude ; Ophthalmologic condition pertinent proliferative retinopathy condition preclude standard ophthalmologic examination . Cataract surgery within 6 month trial ; Vascular lesion anterior segment eye ( infection ulceration cornea , rubeotic glaucoma , etc ) ; Vascular lesion posterior segment eye proliferative retinopathy diabetic , macular edema , s/p photocoagulation macular edema proliferative retinopathy ; nondiabetics central branch retinal vascular occlusion , sickle cell retinopathy , ischemic retinopathy due retinal venous stasis carotid artery disease ) ; Choroidal new vessel associate agerelated macular degeneration , myopic degeneration , presume ocular histoplasmosis syndrome , angioid streak , pseudoxanthoma elasticum , without ocular disease ; Large elevate choroidal nevus , choroidal vascular tumor ( choroidal hemangioma ) , melanoma . Chronic inflammatory disease ( e.g . Crohn , Rheumatoid Arthritis ) ; Active infectious disease and/or know test positive human immunodeficiency virus ( HIV ) , human lymphotrophic virus ( HTLV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) ; Specific laboratory value Screening include : Hemoglobin &lt; 9.0 , g/dL , WBC &lt; 3,000 cell per microliter , platelet count &lt; 75,000/mm3 , Creatinine &gt; 2.0 mg/dL , AST and/or ALT &gt; 3 time upper limit normal clinically significant lab abnormality opinion investigator exclusionary ; Patients undergo enhanced external pulsation ( EECP ) treatment within last 6 month ; Pregnancy lactation ; Severe comorbidity associate reduction life expectancy le 1 year ; Exposure previous experimental angiogenic therapy and/or myocardial laser therapy ; therapy another investigational drug within 180 day enrollment participation concurrent study may confound result study ; Major psychiatric disorder past 6 month ; History recent tobacco abuse ( within past &lt; 5 year ) ; Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>myocardial</keyword>
	<keyword>ischemia</keyword>
	<keyword>coronary disease</keyword>
	<keyword>angina</keyword>
</DOC>